At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 275 enrolled
Drug / intervention
AIN457 +1 moredrug
Likely dose
AIN457 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Extension Trial of Subcutaneously Administered AIN457 in Participants With Moderate to Severe Chronic Plaque-type Psoriasis
In Brief
A Phase 2 clinical trial evaluating AIN457 and Placebo for Plaque-type Psoriasis. Completed, enrolled 275 participants across 57 sites in 7 countries.
Detailed Summary
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque-type Psoriasis
CountriesFrance, Germany, Iceland, Israel, Japan, Norway, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionOct 2016
TodayJul 2026
First PostedMay 28, 2010
Enrollment StartMay 11, 2010
Primary CompletionOct 18, 2016
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 16.1 years ago
Interventions
AIN457drug
AIN457A 150 mg powder for solution
Placebodrug
Placebo to AIN457A 150 mg powder for solution